What is the domestic price difference of clofazimine in capsules with different specifications?

Clofazimine (Clofazimine) is a fat-soluble phenazine antibiotic, mainly used to treat multi-bacillary leprosy (MB type). It is one of the core drugs in the combined leprosy chemotherapy regimen recommended by the World Health Organization. It achieves the purpose of reducing pathogen load, alleviating skin lesions and neuroinflammation by inhibiting the metabolic activity of mycobacteria and inducing immune responses. In actual clinical practice, clofazimine is often used in combination with rifampicin and dapsone to improve efficacy and prevent the development of drug resistance. In recent years, the drug has also been tried to treat non-tuberculous mycobacteria (NTM) infections, especially for certain refractory lung infections. In addition, "off-label use" in lupus erythematosus, chronic granulomatous disease and certain recurrent inflammatory skin diseases has also been gradually discussed, although these applications have not yet been included in the officially approved indications in China.

The market accessibility of clofazimine in China has been significantly improved. Commercial preparations are currently provided by many pharmaceutical companies and have been included in the national medical insurance catalog. It is suitable for patients diagnosed with leprosy. Taking the domestic specification of 50mg*10 capsules as an example, the market price is about 500 yuan. The price may fluctuate slightly due to pharmacy and regional policies. After being included in medical insurance, the out-of-pocket proportion of patients in some areas has been significantly reduced, and the actual drug purchase expenditures are relatively reasonable. For specific reimbursement policies, it is recommended to consult the local medical insurance department or the pharmacy of a top-level hospital to obtain accurate information.

In contrast, there are clofazimine generics with more advantageous prices in overseas markets, such as those produced by pharmaceutical companies in India or Bangladesh.The price is about 400 yuan for 100mg*100 tablets, which is far lower than the domestic unit dose price. Although it is a generic drug, its active ingredients are consistent with the original drug, and its bioequivalence has been approved by multiple national drug regulatory agencies. This has led many patients seeking long-term treatment options to consider obtaining overseas drug sources through formal channels.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine